No, no; it's good. I think we have to talk about intellectual property rights in a broader context here.
In that context, I know that therapeutics for infectious diseases and vaccine development are normally on the low end of the priority list for pharma development. What are the incentives, and what are the reasons for that? Is it our IP protection model or what?